Venus Medtech Hangzhou 2500.HK · HKD

Its shares trade on HKEX under the ticker 2500.HK. It has been listed since 10 December 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥357.7m and a net loss of CN¥475.4m. At that date it held total assets of CN¥2.94bn and shareholders' equity of CN¥2.06bn.

Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2019-12-10. The firm's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Ting Yuk WuNon-Executive Independent Chairman of the BoardCN¥360,000
• Mr. Wang FeiChief Financial Officer
• Mr. Ma LiqiaoExecutive Director, Vice President of Clinical Medicine, since 2019CN¥46,000
• Ms. Liu MeirongVice President, Executive Director, since 2023CN¥1.2m
• Mr. Hou-Sen LimGeneral Manager, Executive Director, since 2016CN¥57,000
• Mr. Wai Chiu WongCompany Secretary
• Mr. Zhang AoNon-Executive Director
• Mr. Wang WeiNon-Executive Director
• Mr. Wai Suen ChiIndependent Non-Executive DirectorCN¥360,000

Overall

84

Environment

72

Social

99

Governance

80

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.